PDE4 Cancer Research Results

PDE4, Phosphodiesterase 4: Click to Expand ⟱
Source:
Type:
Phosphodiesterase 4 (PDE4) has been increasingly implicated in the pathology of Alzheimer's Disease (AD), primarily due to its role in regulating cyclic AMP (cAMP) signaling in the brain.
-Hydrolyzes cAMP → AMP (thus decreasing cAMP levels)
-PDE4 inhibitors (like rolipram): Enhance memory in AD mouse models
Possible inhibitors:
Resveratrol, Baicalin, Luteolin, Quercetin, Apigenin, Icariin


Scientific Papers found: Click to Expand⟱
4986- ATV,  Dipy,    The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer
- Review, Var, NA
HMG-CoA↓, Statins are drugs that have been utilized for years to treat hyperlipidemia through inhibition of the rate-limiting enzyme of the mevalonate (MVA) pathway, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)
AntiAg↑, Dipyridamole (DP), a commonly prescribed anti-platelet agent potentiated the anti-cancer effects of atorvastatin
eff↑, DP-statin combination was synergistic and capable of inducing apoptosis in a variety of acute myelogenous leukemia (AML), MM and breast cancer cell lines.
Apoptosis↑, DP-statin combination also induced apoptosis in primary AML patient samples, but was not toxic to normal PBSCs.
selectivity↑,
*toxicity↓,
TumCG↓, In an in vivo AML tumor model, the DP-statin combination was found to be effective at inhibiting tumor growth.
PDE4↓, DP is known to elicit numerous effects, amongst them, phosphodiesterase (PDE) inhibition
other↑, . As both statins and DP are pre-approved for use in humans, off-patent, and readily available, they have the potential to directly impact patient care.

3785- Bor,    Discovery of boron-containing compounds as Aβ aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease
- Analysis, AD, NA
*Aβ↓, these compounds possessed a significant ability to inhibit self-induced Aβ aggregation (20.5–82.8%, 20 μM) and to act as potential antioxidants
*antiOx↑,
*IronCh↑, Compound 17h also functions as a metal chelator.
*PDE4↓, Some boron-containing compounds have also demonstrated inhibitory activity against the phosphodiesterase 4 enzyme (PDE4) and inflammation-related cytokine release,


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

HMG-CoA↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Migration ⓘ

AntiAg↑, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,   selectivity↑, 1,  

Functional Outcomes ⓘ

PDE4↓, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Functional Outcomes ⓘ

PDE4↓, 1,   toxicity↓, 1,  
Total Targets: 5

Scientific Paper Hit Count for: PDE4, Phosphodiesterase 4
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1361  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page